Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Apr 26, 2022	Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® Reinforces Company’s Robust Intellectual Property Portfolio SOLANA BEACH, Calif. , April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that it has been granted	View HTML PDF Version
Toggle Summary Apr 09, 2015	Evoke Pharma Granted European Union Formulation Patent for EVK-001 SOLANA BEACH, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the European Patent Office has granted the Company European Union (EU) patent no.	View HTML Evoke Pharma Granted European Union Formulation Patent for EVK-001 14.9 KB
Toggle Summary Nov 13, 2019	Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price SOLANA BEACH, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019 , it received notification from the Listing Qualifications Department of	View HTML PDF Version
Toggle Summary Jul 08, 2020	Evoke Pharma Extends Cash Runway to 2Q 2021 Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , July 08, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that as of June 30, 2020 it had cash	View HTML PDF Version
Toggle Summary Jul 06, 2022	Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use SOLANA BEACH, Calif. , July 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Canadian Intellectual	View HTML PDF Version
Toggle Summary Jan 23, 2020	Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ EVERSANA to commercialize and distribute Gimoti in the U.S. EVERSANA to provide $5 million revolving credit facility upon FDA approval SOLANA BEACH, Calif. and CHICAGO , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for	View HTML PDF Version
Toggle Summary May 31, 2017	Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti Company on track for late 2017/early 2018 submission	View HTML Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti 17.6 KB
Toggle Summary Sep 17, 2019	Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™ SOLANA BEACH, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti	View HTML PDF Version
Toggle Summary Sep 12, 2017	Evoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018	View HTML Evoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study 18 KB
Toggle Summary Aug 08, 2016	Evoke Pharma Completes Credit Facility Repayment SOLANA BEACH, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and	View HTML Evoke Pharma Completes Credit Facility Repayment 14.2 KB